期刊文献+

OOS系统、偏差管理系统和CAPA系统比较 被引量:6

Comparison of Systems of OOS,Deviation Management and CAPA
原文传递
导出
摘要 制药企业为了保证产品质量,必须确保质量管理体系正常运行。但是,由于质量系统组成的庞大和复杂性,每个制药企业的质量保证系统都处于波动变化中。因而,制药企业针对质量系统的关键要素,需要持续地,定期地对质量系统进行维护和纠正。在GMP质量管理学发展过程中,偏差管理系统、OOS系统和CAPA系统是不同历史阶段出现的质量系统维护工具。为了帮助制药企业更好的理解和应用这些工具,作者结合自己的工作经验和相关指南、著作,对这3个系统进行比较和分析,并系统研究各自特点和差异。 In order to keep acceptable quality of drugs,pharmaceutical enterprises must ensure the normal operation of quality system. However,in view of that quality system may be cumbersome and complex,the quality system in all pharmaceutical enterprises will be always changed. Then,continuous and periodical maintenance of quality system should be carried out with respect to the key elements in the system. In the development of GMP quality administration,all of deviation management system,OOS system and CAPA system,which appeared in different historic stages,are the maintenance tools of quality system. In order to help enterprises understand and apply these tools well,in this article,combined with work experiences and guides,these three tools were analyzed and compared in their characteristics and differences.
出处 《医药工程设计》 2010年第5期17-20,共4页 Pharmaceutical Engineering Design
关键词 质量 GMP OOS 偏差 CAPA QBD quality GMP OOS deviation CAPA QBD
  • 相关文献

参考文献4

  • 1ICH Q7 《good manufacturing practice for API》.
  • 2FDA guide 《Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production》.
  • 321CFR820 《 quality system regulation 》.
  • 4PDA网站培训资料.

同被引文献46

  • 1梁毅.浅析无菌药品的参数放行[J].医药工程设计,2007,28(4):1-4. 被引量:3
  • 2中华人民共和国卫生部.药品生产质量管理规范[s].北京:中华人民共和国卫生部,2011.
  • 3药品GMP指南[M].北京:中国医药科技出版社.2011.
  • 4ICH Q10 Pharmaceutical Quality System[ EB/OL]. [2008 -06 - 04]. http://www, fda. gov/Regulatory-Information/Guidances/ ucm128030, htm.
  • 5Volume g-EU Gudelines to Good Manufacturing Practice Medici- nal Products for Human and Veterinary Use [ EB/OL]. http:// lib. shilinx, com/wiki/index, php? title = EU.
  • 6European Parliament and the Council of the Euopean Union. Di- rective 2001/83/EC of 6 November 2001 on the Community code relating to medicinal products for human use[ J]. OffJ Eur Com- mun,2001,11 (28) :82.
  • 7杨俊坚.无菌药品附录为制剂接轨国际开路一新版GMP引入国际通用的A、B、C、D四级无菌标准[N].医药经济报,2011-02-23(A01).
  • 8Koppel H,Schneider B,Watzig H.Out-of-specification Test Results from the Statistical Point of View[J].Journal of Pharmaceutical and Biomedical Analysis,2007,44:718-829.
  • 9CDER,FDA,DHHS.Draft Guidance for Industry:Investigating out of Specification(OOS)Test Results for Pharmaceutical Production.Bethesda Md[S].1998.
  • 10US FDA(2006)Guidance for Industry.Investigating Outof-specification(OOS)Test Results for Pharmaceutical Production[S].2006.

引证文献6

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部